2022 - Research.com Best Scientist Award
John G.F. Cleland mainly focuses on Heart failure, Internal medicine, Cardiology, Ejection fraction and Heart disease. John G.F. Cleland has researched Heart failure in several fields, including Surgery, Blood pressure, Intensive care medicine, Myocardial infarction and Atrial fibrillation. His research on Internal medicine often connects related topics like Endocrinology.
His research in Cardiology focuses on subjects like Hazard ratio, which are connected to Proportional hazards model. His Ejection fraction study combines topics in areas such as Interquartile range, Intention-to-treat analysis, Clinical endpoint, Ventricular remodeling and Pulmonary wedge pressure. His research integrates issues of Anesthesia, Rolofylline, Cardiomyopathy, Circulatory system and Micronutrient in his study of Heart disease.
The scientist’s investigation covers issues in Heart failure, Internal medicine, Cardiology, Ejection fraction and Intensive care medicine. His Heart failure research is multidisciplinary, relying on both Heart disease, Randomized controlled trial, Atrial fibrillation and Clinical trial. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Surgery.
His work in Cardiac resynchronization therapy, Coronary artery disease, Carvedilol, Sinus rhythm and Stroke volume are all subfields of Cardiology research. His biological study spans a wide range of topics, including Natriuretic peptide and Interquartile range. The various areas that John G.F. Cleland examines in his Intensive care medicine study include Disease and MEDLINE.
John G.F. Cleland focuses on Heart failure, Internal medicine, Cardiology, Ejection fraction and In patient. His work carried out in the field of Heart failure brings together such families of science as Blood pressure, Clinical endpoint, Cohort and Atrial fibrillation. His research in Atrial fibrillation intersects with topics in Text mining and MEDLINE.
His studies in Hazard ratio, Confidence interval, Coronary artery disease, Interquartile range and Clinical trial are all subfields of Internal medicine research. His study in Sinus rhythm, Myocardial infarction, Stroke volume, Heart failure with preserved ejection fraction and Rivaroxaban falls under the purview of Cardiology. His research investigates the connection between Ejection fraction and topics such as Omecamtiv mecarbil that intersect with issues in Cardiac function curve.
John G.F. Cleland spends much of his time researching Heart failure, Internal medicine, Cardiology, Ejection fraction and Hazard ratio. His Heart failure study combines topics from a wide range of disciplines, such as Clinical trial and Intensive care medicine. His Internal medicine research focuses on Coronary artery disease, Cohort, Confidence interval, Randomized controlled trial and Disease.
His study in Atrial fibrillation, Rivaroxaban, Sinus rhythm, Myocardial infarction and Cardiac function curve is carried out as part of his studies in Cardiology. His Ejection fraction research is multidisciplinary, incorporating perspectives in Interquartile range, Cohort study, Transferrin saturation, Management of heart failure and Prospective cohort study. His research integrates issues of Body mass index and Gastroenterology in his study of Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski;Adriaan A. Voors;Stefan D. Anker;Héctor Bueno.
European Journal of Heart Failure (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski;Adriaan A Voors;Stefan D Anker;Héctor Bueno.
European Heart Journal (2016)
The effect of cardiac resynchronization on morbidity and mortality in heart failure
John G.F. Cleland;Jean-Claude Daubert;Erland Erdmann;Nick Freemantle.
web science (2005)
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.
Karl Swedberg;John Cleland;Henry Dargie;Helmut Drexler.
European Heart Journal (2005)
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy : The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)
Michele Brignole;Angelo Auricchio;Gonzalo Baron-Esquivias;Pierre Bordachar.
European Heart Journal (2013)
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
Philip A. Poole-Wilson;Karl Swedberg;John G.F. Cleland;Andrea Di Lenarda.
The Lancet (2003)
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.
J.G.F Cleland;K Swedberg;F Follath;M Komajda.
European Heart Journal (2003)
beta Blockade after myocardial infarction: systematic review and meta regression analysis.
Nick Freemantle;John Cleland;Philip Young;James Mason.
Rosuvastatin in Older Patients with Systolic Heart Failure
John Kjekshus;Eduard Apetrei;Vivencio Barrios;Michael Böhm.
The New England Journal of Medicine (2007)
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
John G.F. Cleland;Michal Tendera;Jerzy Adamus;Nick Freemantle.
European Heart Journal (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: